BioCentury | Jul 20, 2019
Emerging Company Profile

China Ophthalmology Focus eyes Asia market

Spun out from Lee’s in May and aiming for its first NDA submissions next year, China Ophthalmology Focus is already looking ahead to a Hong Kong IPO and an expansion into other Asian markets with...
BC Week In Review | Jul 18, 2016
Clinical News

Adapalene 0 regulatory update

Galderma said Japan approved Epiduo adapalene/benzoyl peroxide to treat acne vulgaris. Galderma expects partner Maruho to launch the once-daily gel formulation of 0.1% adapalene and 2.5% benzoyl peroxide in the country this year. Earlier this...
BC Week In Review | Sep 7, 2015
Company News

Galderma sales and marketing update

Galderma launched Epiduo Forte adapalene/benzoyl peroxide in the U.S. to treat acne vulgaris. The wholesale acquisition cost (WAC) for 45 g of the product is $398.10. Epiduo Forte is a once-daily topical gel formulation of...
BC Week In Review | Aug 3, 2015
Clinical News

Epiduo Forte adapalene 0 regulatory update

FDA approved an NDA from Galderma for Epiduo Forte adapalene/benzoyl peroxide to treat acne vulgaris. The company said it plans to launch the once-daily topical gel formulation of adapalene 0.3%, a synthetic retinoid, and benzoyl...
BC Week In Review | Apr 6, 2015
Clinical News

Adapalene 0: Phase III data

A double-blind Phase III trial in 503 patients ages >=12 with moderate to severe acne showed that once-daily 0.3% A/BPO met the co-primary endpoints of improving the success rate (33.7% vs. 11%, p<0.001) and of...
BC Week In Review | Feb 25, 2013
Clinical News

Epiduo adapalene/benzoyl peroxide regulatory update

Galderma said FDA approved an sNDA for Epiduo adapalene/benzoyl peroxide gel to treat acne vulgaris in patients 9 years and older. The gel formulation of adapalene and benzoyl peroxide, which Galderma said is immediately available,...
BC Week In Review | Jun 7, 2010
Company News

Galderma sales and marketing update

Galderma launched its Epiduo adapalene/benzoyl peroxide in the U.K. to treat acne vulgaris when comedones, papules and pustules are present. The price for the gel formulation of adapalene and benzoyl peroxide is £17.91 ($25.96). Galderma...
BC Week In Review | Mar 29, 2010
Clinical News

Adapalene regulatory update

FDA approved an NDA from Galderma for Differin Lotion 0.1% to treat acne vulgaris in patients ages 12 and older. The company plans to launch the topical naphthoic acid derivative with retinoid-like activities next month....
BC Week In Review | Mar 1, 2010
Clinical News

Epiduo adapalene/benzoyl peroxide: Post-marketing study data

The double-blind, post-marketing ACCESS trial in 459 patients showed that topical once-daily Epiduo plus 100 mg once-daily oral doxycycline met the primary endpoint of reducing total lesion count at week 12 vs. gel vehicles plus...
BC Week In Review | Dec 15, 2008
Clinical News

Epiduo adapalene/benzoyl peroxide regulatory update

FDA approved an NDA from Galderma for Epiduo adapalene/benzoyl peroxide (0.1%/2.5%) cream to treat acne vulgaris in patients 12 years and older. Galderma S.A. , Lausanne, Switzerland   Product: Epiduo adapalene/benzoyl peroxide   Business: Dermatology  ...
Items per page:
1 - 10 of 12